Heavy chain only antibodies: A new paradigm in personalized HER2+ breast cancer therapy

Seyed Moghimi, Fatemeh Rahbarizadeh, Davoud Ahmadvand, Ladan Parhamifar

Research output: Contribution to journalEditorial

11 Scopus citations

Abstract

Unlike conventional antibodies, heavy chain only antibodies derived from camel contain a single variable domain (VHH) and two constant domains (CH2 and CH3). Cloned and isolated VHHs possess unique properties that enable them to excel conventional therapeutic antibodies and their smaller antigen-binding fragments in cancer targeting and therapy. VHHs express low immunogenicity, are highly robust and easy to manufacture and have the ability to recognize hidden or uncommon epitopes. We highlight the utility of VHH in design of new molecular, multifunctional particulate and immune cell-based systems for combating HER2+ breast cancer.

Original languageEnglish (US)
Pages (from-to)1-4
Number of pages4
JournalBioImpacts
Volume3
Issue number1
DOIs
StatePublished - Mar 26 2013

Keywords

  • Chimeric antigen receptors
  • Heavy chain only antibodies
  • HER2
  • Nanotechnology
  • Single variable domain

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmaceutical Science
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Heavy chain only antibodies: A new paradigm in personalized HER2+ breast cancer therapy'. Together they form a unique fingerprint.

Cite this